Immunic is a biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. The company is developing three small molecule products: IMU-838 is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme dihydroorotate dehydrogenase; IMU-935 is an inverse agonist of RORgt; and IMU-856 targets the restoration of the intestinal barrier function. The company's main development program, IMU-838, is in Phase 2 clinical development for relapsing-remitting multiple sclerosis and ulcerative colitis, with an additional Phase 2 trial considered in Crohn's disease.

Kingsway Financial Services is a holding company. Through its subsidiaries, Co. operates as a merchant bank engaged in the property and casualty insurance business. Co. operates three segments: Insurance Underwriting, which markets automobile insurance products that provide coverage in three main areas: liability, accident benefits and physical damage; Insurance Services, which includes IWS Acquisition Corporation, a licensed motor vehicle service agreement company, and Trinity Warranty Solutions LLC, a provider of warranty products and maintenance support; and Leased Real Estate, which includes Co.'s subsidiary, CMC Industries, Inc., that owns a parcel of real property located in Texas.

Kodiak Sciences is a clinical stage biopharmaceutical company focusing on therapeutics to treat chronic, high-prevalence retinal diseases. The company's main product candidate is KSI-301, a biologic therapy built with the company's antibody biopolymer conjugate platform, which is designed to maintain drug levels in ocular tissues. KSI-301 is used to treat patients with wet age-related macular degeneration, diabetic retinopathy, including diabetic macular edema, and macular edema due to retinal vein occlusion. The company has applied its antibody biopolymer conjugate platform to develop additional product candidates beyond KSI-301, including KSI-501, its bispecific anti-IL-6/VEGF bioconjugate.

NGM Biopharmaceuticals is a biopharmaceutical company. The company is focused on the following programs: Aldafermin, which is for the treatment of non-alcoholic steatohepatitis (NASH); NGM313 (MK-3655), which is for the treatment of NASH and type 2 diabetes; NGM120, which is designed to block the effects of elevated growth differentiation factor 15 levels on cancer anorexia/cachexia syndrome, and, possibly, tumors; NGM217, which is designed to restore pancreatic islet function and increase insulin production in patients with diabetes; NGM621, which is designed to decrease levels of this protein implicated in the dry form of AMD; and NGM395, which is for the treatment of metabolic syndrome.

Quest Resource Holding is a provider of reuse, recycling, and disposal services. The company provides businesses across industry sectors with single source solutions for the reuse, recycling, and disposal of a variety of waste streams and recyclables generated by their operations. The company's customers are multi-location businesses for which it creates, implements, and manages customer-specific programs for the collection, processing, recycling, disposal, and tracking of waste streams and recyclables. The company's sustainability programs include planning, writing policies and procedures, LEED certification, life cycle assessment, energy modeling, building commissioning, and carbon emission reduction reporting.

Schweitzer-Mauduit International is a producer of materials, including papers, nets and films. The company operates and manages two reportable segments based on product lines: Advanced Materials and Structures, which manufactures resin-based products used in applications in the filtration, infrastructure and construction, transportation, industrial, and medical end-markets; and Engineered Papers, which produces cigarette papers and reconstituted tobacco products for cigarette and cigar manufacturers, as well as various other non-tobacco paper products.

Texas Capital Bancshares is a bank holding company. Through its subsidiary, Texas Capital Bank, National Association, the company serves commercial businesses and professionals and entrepreneurs located in Texas as well as operates several lines of business serving a regional or national clientele of commercial borrowers. The company is a lender, with most of its loans held for investment, excluding mortgage finance loans and other national lines of business, being made to businesses headquartered or with operations in Texas. The company's business deposit products include commercial checking accounts, lockbox accounts, cash concentration accounts and other treasury management services, including online banking.

Tricida is a pharmaceutical company focused on the development and commercialization of its drug candidate, TRC101 (veverimer), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis by binding and removing acid from the gastrointestinal tract.